DrugPatentWatch Database Preview
RITUXAN HYCELA Drug Profile
Summary for Tradename: RITUXAN HYCELA
| Patents: | 714 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for RITUXAN HYCELA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RITUXAN HYCELA |
Recent Clinical Trials for RITUXAN HYCELA
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Emory University | Phase 2 |
| Genentech, Inc. | Phase 2 |
| Acerta Pharma BV | Phase 1 |
Recent Litigation for RITUXAN HYCELA
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD. | 2019-07-12 |
| CELGENE CORPORATION v. APOTEX INC. | 2019-06-19 |
| Genentech, Inc. v. Pfizer Inc. | 2019-04-05 |
See all RITUXAN HYCELA litigation
PTAB Litigation
| Petitioner | Date |
|---|---|
| Celltrion, Inc. | 2018-05-04 |
| Apotex Inc. | 2018-02-23 |
| Forty Seven, Inc. | 2018-01-08 |
Patent Text Search: US Patents for RITUXAN HYCELA
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR) | 2032-09-12 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | Pharmacyclics LLC (Sunnyvale, CA) | 2030-06-03 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | Array BioPharma Inc. (Boulder, CO) | 2028-10-22 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for RITUXAN HYCELA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | I419903 | Start Trial |
| Japan | WO2008026769 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2007016466 | Start Trial |
| Mexico | PA04003535 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for RITUXAN HYCELA
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 122017000101 | Germany | Start Trial | PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170623 |
| 300822 | Netherlands | Start Trial | PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326 |
| C201730059 | Spain | Start Trial | PRODUCT NAME: INOTUZUMAB OZOGAMICINA; NATIONAL AUTHORISATION NUMBER: EU/1/17/1200; DATE OF AUTHORISATION: 20170629; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1200; DATE OF FIRST AUTHORISATION IN EEA: 20170629 |
| CR 2017 00053 | Denmark | Start Trial | PRODUCT NAME: ANTISTOF-LAEGEMIDDEL-KONJUGAT, HVORI ET CD22-RETTET ANTISTOF ER KOVALENT BUNDET TIL N-ACETYL-GAMMA-CALICHEAMICIN DIMETHYLHYDRAZID, SVARENDE TIL INOTUZUMAB OZOGAMICIN; REG. NO/DATE: EU/1/17/1200 20170703 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
